J&J to acquire Crucell for $2.3 billion
September 17, 2010Sales and Marketing Crucell, Johnson & Johnson
Johnson & Johnson is set to buy out Crucell for around $2.3 billion (1.75 bn euros) expanding its presence in …
Triple account win for M:Communications
September 17, 2010Medical Communications Axis Shield, M:Communications, Medivir, Virgin Healthcare, medical communications
London-based communications consultancy M:Communications has won three new healthcare accounts. The new business comes from in vitro diagnostic company Axis-Shield, …
GSK switches to subcutaneous route for antibody
September 16, 2010Research and Development Arzerra, Genmab, GlaxoSmithKline, ofatumumab
GlaxoSmithKline says it will switch development of a new antibody treatment to a subcutaneous injection, to make it more commercially …
Norgine appoints global quality director
September 16, 2010Manufacturing and Production, Research and Development Norgine, appointment, manufacturing and production, research and development
Rosemarie Corrigan has joined European specialty pharmaceutical company Norgine as director of global quality, taking a leadership role across a …
MSD’s Dan Heapy joins MSI
September 16, 2010Sales and Marketing MSI, appointment, sales and marketing
The MSI Consultancy has appointed Dan Heapy as a consultant. He joins MSI from MSD, where over five years he …
Gene therapy advance hailed for thalassemia
September 16, 2010Research and Development Bluebird Bio, gene therapy, thalassemia
A new gene therapy for one of the most frequently inherited genetic disorders has produced promising results. The trial by …
Novo expands diabetes research in China
September 16, 2010Research and Development China, Novo Nordisk, diabetes
Diabetes is at the core of Novo Nordisk’s latest investment in China, where the company plans to more than double …
Digital Pharma: Lilly aims to be social on its Lillypad
September 16, 2010Medical Communications Digital Pharma blog, Twitter, blog, lilly
Lilly has jumped feet first into the social media scene this week, launching a corporate blog and a Twitter account. …
AstraZeneca’s Brilinta delayed
September 16, 2010Sales and Marketing Brillinta, Effient, Plavix, clopidogrel
AstraZeneca’s blood thinning drug Brilinta faces an extra three month delay to its review by the FDA. The US regulator …
Representing medium-sized pharma
September 16, 2010Sales and Marketing European Medicines Group, UCB
UCB’s Matthew Speers is the new chairman of the European Medicines Group, which represents European-owned pharma companies in the UK. …
GSK’s leukaemia drug rejected by NICE
September 16, 2010Sales and Marketing Arzerra, GSK, NHS, NICE
GSK’s leukaemia treatment Arzerra has been rejected by NICE, which says the drug does not represent good value for the …
Gilenya approved in Russia, awaits FDA decision
September 16, 2010Sales and Marketing Cladribine, Gilena, MS
Novartis has won approval for its MS drug Gilenya in Russia but still awaits the FDA’s decision on its fate …
Pepscan and Tibotec sign peptides deal
September 15, 2010Research and Development, Sales and Marketing CLIPS, HIV, J&J, JJ, Pepscan, Tibotec
Pepscan Therapeutics, the biotech firm focusing on protein mimicry technology has signed a deal with Tibotec. Netherlands-based Pepscan will use …
FDA warns BMS over manufacturing plant in Puerto Rico
September 15, 2010Manufacturing and Production BMS, FDA, GMP, Puerto Rico
A plant operated by Bristol-Myers Squibb in Puerto Rico has been cited by the US Food and Drug Administration for …
New Commercial Realities – Part 1: Key drivers of the evolving pharmaceutical landscape
September 15, 2010Faced with a changing healthcare environment and the prospect of diminishing commercial returns, the pharmaceutical industry has recognised that traditional …
New Commercial Realities – Part 1: Key drivers of the evolving pharmaceutical landscape
September 15, 2010Faced with a changing healthcare environment and the prospect of diminishing commercial returns, the pharmaceutical industry has recognised that traditional …
New Commercial Realities – Part 1: Key drivers of the evolving pharmaceutical landscape
September 15, 2010Faced with a changing healthcare environment and the prospect of diminishing commercial returns, the pharmaceutical industry has recognised that traditional …
New Commercial Realities – Part 1: Key drivers of the evolving pharmaceutical landscape
September 15, 2010Faced with a changing healthcare environment and the prospect of diminishing commercial returns, the pharmaceutical industry has recognised that traditional …
Latest content
Five Facts about NHS and primary care
AI in pharma: From lab development to patient impact
